{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T03:04:36Z","timestamp":1768964676933,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,20]]},"DOI":"10.7759\/cureus.101905","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:55:42Z","timestamp":1768920942000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Biologics in the Management of Pediatric Asthma: A Single-Center Retrospective Study"],"prefix":"10.7759","author":[{"given":"Andy P","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahima","family":"Silas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie  G","family":"Cherian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floyd R","family":"Livingston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.01.002","article-title":"Biologics in the treatment of asthma in children and adolescents","volume":"151","author":"Bacharier LB","year":"2023","unstructured":"Bacharier LB, Jackson DJ. Biologics in the treatment of asthma in children and adolescents. J Allergy Clin Immunol. 2023, 151:581-9. 10.1016\/j.jaci.2023.01.002","journal-title":"J Allergy Clin Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00558-2023","article-title":"Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study","volume":"62","author":"Fiocchi AG","year":"2023","unstructured":"Fiocchi AG, Phipatanakul W, Zeiger RS, et al.. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study. Eur Respir J. 2023, 62:2300558. 10.1183\/13993003.00558-2023","journal-title":"Eur Respir J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00303-X","article-title":"Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study","volume":"12","author":"Bacharier LB","year":"2024","unstructured":"Bacharier LB, Maspero JF, Katelaris CH, et al.. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study. Lancet Respir Med. 2024, 12:45-54. 10.1016\/S2213-2600(23)00303-X","journal-title":"Lancet Respir Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.08.038","article-title":"Dupilumab efficacy in children with type 2 asthma receiving high- to medium-dose inhaled corticosteroids (VOYAGE)","volume":"12","author":"Maspero JF","year":"2024","unstructured":"Maspero JF, Antila MA, Deschildre A, et al.. Dupilumab efficacy in children with type 2 asthma receiving high- to medium-dose inhaled corticosteroids (VOYAGE). J Allergy Clin Immunol Pract. 2024, 12:3303-12. 10.1016\/j.jaip.2024.08.038","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2023.100837","article-title":"Unanswered questions on the use of biologics in pediatric asthma","volume":"16","author":"Nieto A","year":"2023","unstructured":"Nieto A, El-Sayed ZA, G\u00f3mez RM, et al.. Unanswered questions on the use of biologics in pediatric asthma. World Allergy Organ J. 2023, 16:100837. 10.1016\/j.waojou.2023.100837","journal-title":"World Allergy Organ J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach SJ","year":"2015","unstructured":"Teach SJ, Gill MA, Togias A, et al.. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015, 136:1476-85. 10.1016\/j.jaci.2015.09.008","journal-title":"J Allergy Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199705083361904","article-title":"The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma","volume":"336","author":"Rosenstreich DL","year":"1997","unstructured":"Rosenstreich DL, Eggleston P, Kattan M, et al.. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med. 1997, 336:1356-63. 10.1056\/NEJM199705083361904","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.021","article-title":"Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma","volume":"124","author":"Lanier B","year":"2009","unstructured":"Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009, 124:1210-6. 10.1016\/j.jaci.2009.09.021","journal-title":"J Allergy Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris PA","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009, 42:377-81. 10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inform"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris PA","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al.. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019, 95:103208. 10.1016\/j.jbi.2019.103208","journal-title":"J Biomed Inform"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.2.e36","article-title":"Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)","volume":"108","author":"Milgrom H","year":"2001","unstructured":"Milgrom H, Berger W, Nayak A, et al.. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001, 108:E36. 10.1542\/peds.108.2.e36","journal-title":"Pediatrics"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro M","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, et al.. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018, 378:2486-96. 10.1056\/NEJMoa1804092","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier LB","year":"2021","unstructured":"Bacharier LB, Maspero JF, Katelaris CH, et al.. Dupilumab in children with uncontrolled moderate-to-severe asthma. N Engl J Med. 2021, 385:2230-40. 10.1056\/NEJMoa2106567","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega HG","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, et al.. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014, 371:1198-207. 10.1056\/NEJMoa1403290","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald JM","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, et al.. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016, 388:2128-41. 10.1016\/S0140-6736(16)31322-8","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker ER","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, et al.. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016, 388:2115-27. 10.1016\/S0140-6736(16)31324-1","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow A","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A, et al.. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021, 384:1800-9. 10.1056\/NEJMoa2034975","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/443892-efficacy-of-biologics-in-the-management-of-pediatric-asthma-a-single-center-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:55:42Z","timestamp":1768920942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/443892-efficacy-of-biologics-in-the-management-of-pediatric-asthma-a-single-center-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.101905","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}